Literature DB >> 19542623

SPECT predictors of cognitive decline and Alzheimer's disease in mild cognitive impairment.

Flavio Nobili1, Fabrizio De Carli, Giovanni B Frisoni, Florence Portet, Frans Verhey, Guido Rodriguez, Anna Caroli, Jacques Touchon, Silvia Morbelli, Ugo P Guerra, Barbara Dessi, Andrea Brugnolo, Pieter Jelle Visser.   

Abstract

Baseline brain single photon emission computed tomography (SPECT) was evaluated in eighty subjects with mild cognitive impairment (MCI) who were followed for a mean of about two years, when twelve patients developed Alzheimer's disease (AD), nineteen showed memory decline (D), and forty-three had normal cognition assessment (stable: S) (six drop-out). Volumetric Regions of Interest (VROI) analysis was performed in six associative cortical areas in each hemisphere. ANOVA for repeated measures showed significant effects for both the group (S, D, and AD; p < 0.004) and VROI (p < 0.0001) factors, with significant group*region interaction (p < 0.01). At post-hoc comparison, hippocampal VROIs values were lower in AD than in D and S, while parietal VROIs values were lower in D and AD than in S. These four VROI significantly correlated with verbal delayed recall score at follow-up visit. Receiver operating characteristic (ROC) curves for the mean hippocampal VROI value showed 0.81 sensitivity with 0.86 specificity in separation of S+D from AD (p < 0.0001), and 0.69 sensitivity with 0.75 specificity in separation of S from D+AD (p < 0.0002). ROC curves for the mean parietal VROI value showed 0.62 sensitivity with 0.70 specificity in separation of S from D+AD (p < 0.0002). Baseline SPECT can support outcome prediction in subjects with MCI.

Entities:  

Mesh:

Year:  2009        PMID: 19542623     DOI: 10.3233/JAD-2009-1091

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  13 in total

1.  A two-year follow-up of cognitive deficits and brain perfusion in mild cognitive impairment and mild Alzheimer's disease.

Authors:  Montserrat Alegret; Gemma Cuberas-Borrós; Georgina Vinyes-Junqué; Ana Espinosa; Sergi Valero; Isabel Hernández; Isabel Roca; Agustín Ruíz; Maitée Rosende-Roca; Ana Mauleón; James T Becker; Joan Castell-Conesa; Lluís Tárraga; Mercè Boada
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  Cognitive, genetic, and brain perfusion factors associated with four year incidence of Alzheimer's disease from mild cognitive impairment.

Authors:  Montserrat Alegret; Gemma Cuberas-Borrós; Ana Espinosa; Sergi Valero; Isabel Hernández; Agustín Ruíz; James T Becker; Maitée Rosende-Roca; Ana Mauleón; Oscar Sotolongo; Joan Castell-Conesa; Isabel Roca; Lluís Tárraga; Mercè Boada
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

3.  Glucose metabolism in normal aging and Alzheimer's disease: Methodological and physiological considerations for PET studies.

Authors:  Lisa Mosconi
Journal:  Clin Transl Imaging       Date:  2013-08

4.  Rutin protects against cognitive deficits and brain damage in rats with chronic cerebral hypoperfusion.

Authors:  Jie Qu; Qiong Zhou; Ying Du; Wei Zhang; Miao Bai; Zhuo Zhang; Ye Xi; Zhuyi Li; Jianting Miao
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

5.  Differential focal and nonfocal prospective memory accuracy in a demographically diverse group of nondemented community-dwelling older adults.

Authors:  Susan Y Chi; Laura A Rabin; Avner Aronov; Joshua Fogel; Ashu Kapoor; Cuiling Wang
Journal:  J Int Neuropsychol Soc       Date:  2014-11-17       Impact factor: 2.892

6.  Imaging the Alzheimer brain.

Authors:  J Wesson Ashford; Ahmad Salehi; Ansgar Furst; Peter Bayley; Giovanni B Frisoni; Clifford R Jack; Osama Sabri; Maheen M Adamson; Kerry L Coburn; John Olichney; Norbert Schuff; Daniel Spielman; Steven D Edland; Sandra Black; Allyson Rosen; David Kennedy; Michael Weiner; George Perry
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

7.  Brain perfusion correlates of visuoperceptual deficits in mild cognitive impairment and mild Alzheimer's disease.

Authors:  Montserrat Alegret; Georgina Vinyes-Junqué; Mercè Boada; Pablo Martínez-Lage; Gemma Cuberas; Ana Espinosa; Isabel Roca; Isabel Hernández; Sergi Valero; Maitée Rosende-Roca; Ana Mauleón; James T Becker And; Lluís Tárraga
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

8.  (99m)Tc hexamethyl-propylene-aminoxime single-photon emission computed tomography prediction of conversion from mild cognitive impairment to Alzheimer disease.

Authors:  D P Devanand; Ronald L Van Heertum; Lawrence S Kegeles; Xinhua Liu; Zong Hao Jin; Gnanavalli Pradhaban; Henry Rusinek; Mali Pratap; Gregory H Pelton; Isak Prohovnik; Yaakov Stern; J John Mann; Ramin Parsey
Journal:  Am J Geriatr Psychiatry       Date:  2010-11       Impact factor: 4.105

Review 9.  Mild cognitive impairment in Parkinson disease: heterogenous mechanisms.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2012-02-18       Impact factor: 3.575

10.  Prediction of outcomes in MCI with (123)I-IMP-CBF SPECT: a multicenter prospective cohort study.

Authors:  Kengo Ito; Etsuro Mori; Hidenao Fukuyama; Kazunari Ishii; Yukihiko Washimi; Takashi Asada; Satoru Mori; Kenichi Meguro; Shin Kitamura; Haruo Hanyu; Seigo Nakano; Hiroshi Matsuda; Yasuo Kuwabara; Kazuo Hashikawa; Toshimitsu Momose; Yoshitaka Uchida; Jun Hatazawa; Satoshi Minoshima; Kenji Kosaka; Tatsuo Yamada; Yoshiharu Yonekura
Journal:  Ann Nucl Med       Date:  2013-09-06       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.